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Abstract: The pathway leading from beta-amyloid deposition to cognitive 
impairment is believed to be a cornerstone of the pathogenesis of 
Alzheimer's disease (AD). However, what drives amyloid build-up in 
sporadic non-genetic cases of AD is still unknown. AD brains feature an 
inflammatory reaction around amyloid plaques, and a specific subset of 
the gut microbiota (GMB) may promote brain inflammation.  
We investigated the possible role of the GMB in AD pathogenesis by 
studying the association of brain amyloidosis with (i) GMB taxa with pro- 
and anti-inflammatory activity, and (ii) peripheral inflammation in 
cognitively impaired patients. 
We measured the stool abundance of selected bacterial GMB taxa 
(Escherichia/Shigella, Pseudomonas aeruginosa, Eubacterium rectale, 
Eubacterium hallii, Faecalibacterium prausnitzii and Bacteroides 
fragilis) and the blood expression levels of cytokines (pro-inflammatory 
cytokines: CXCL2, CXCL10, IL-1β, IL-6, IL-18, IL-8, NLRP3, TNF-α; anti-
inflammatory cytokines: IL-4, IL-10, IL-13) in cognitively impaired 
patients with (n=40, Amy+) and with no brain amyloidosis (n=33, Amy-), 
and also in a group of controls (n=10, no brain amyloidosis and no 
cognitive impairment, HC). 
Amy+ patients showed higher levels of pro-inflammatory cytokines (IL-6, 
CXCL2, NLRP3 and IL-1β) compared to both controls and to Amy- patients. A 
reduction of the anti-inflammatory cytokine IL-10 was observed in Amy+ 
versus Amy-. Amy+ showed lower abundance of Eubacterium rectale and 
higher abundance of Escherichia/Shigella as compared to both HC (Fold 
Change, FC=-9.6, p<0.001 and FC=+12.8, p<0.001, respectively) and to Amy- 
(FC=-7.7, p<0.001 and FC=+7.4, p=0.003). A positive correlation was 
observed between pro-inflammatory cytokines IL-1β, NLRP3 and CXCL2 with 
abundance of the inflammatory bacteria taxon Escherichia/Shigella 
(rho=0.60, p<0.001; rho=0.57, p<0.001; and rho=0.30, p=0.007, 
respectively) and a negative correlation with the anti-inflammatory 
Eubacterium rectale (rho=-0.48, p<0.001; rho=-0.25, p=0.024; rho=-0.49, 
p<0.001).  
Our data indicate that an increase in the abundance of a pro-inflammatory 
GMB taxon, Escherichia/Shigella, and a reduction in the abundance of an 
anti-inflammatory taxon, Eubacterium rectale, are possibly associated 
with a peripheral inflammatory state in patients with cognitive 
impairment and brain amyloidosis. A possible causal relation between GMB-
related inflammation and amyloidosis deserves further investigation. 
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*Verification
Highlights 
 
x We aimed to investigate the possible role of the GMB in AD pathogenesis  
x GMB taxa were measured in the stools and inflammatory cytokines in the blood of Amy-, 
Amy+ cognitively impaired patients and controls; 
x Amy+ patients have higher abundance of pro-inflammatory GMB taxa and higher 
peripheral inflammation 
x pro-inflammatory GMB composition is associated with peripheral inflammation in patients 
with cognitive impairment and brain amyloidosis 
*Highlights (for review)
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Brescia, August 23rd, 2016 
 
 
 
Dear Prof Rapp, 
 
We thank you for the possibility to improve our manuscript by addressing the comments of reviewer 2. We 
are particularly encouraged by the positive appraisal of the other two reviewers who have not commented 
further. The latest revisions have been highlighted in yellow for your convenience.  
 
Please find attached revision 2 of our manuscript entitled “Association of brain amyloidosis with pro-
inflammatory gut bacterial strains and peripheral inflammation markers in cognitively impaired elderly” 
that we re-submit as a Research Article to Neurobiology of Aging.  
 
We hope that you will find this version suitable for publication in your journal. 
 
 
Yours sincerely,  
 
 
 
Annamaria Cattaneo, on behalf of all authors 
 
 
 
 
 
 
 
*Rebuttal Letter
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Reviewers' comments to revision 1 
 
 
Reviewer #2 
x The manuscript has considerably improved during this first revision and the authors have improved their 
statistical analysis. Also healthy controls have been included. Unfortunately figure reproduction in the PDF 
is very bad so it is difficult to evaluate the figures in detail. 
We are sorry to read that this reviewer could not evaluate the figures in detail. We have taken the freedom to 
download ourselves the PDF file from Elsevier’s Editorial System. By clicking the link “download high 
resolution figure” at the top of each figure, we could easily download the high resolution version of the 
figures.  
x However, to me, the parts of the presentation of the results is difficult to follow and I would suggest to 
include more supportive material in the supplement. Some native English language editing support could be 
worthwhile. There are still some statistical aspects that need to be clarified. The authors now use GLMs with 
a gamma distribution for confounder adjustment which is appropriate. However, they post hoc selected 
confounders based on correlations between taxa and clinical variables. Apparently this led them to use GLM 
only for Pseudomonas? Since in this case not many taxa have been studied and also the number of clinical 
variables is limited, it would be preferable to use such GLM adjustment (using eg, MMSE and BMI, and 
medication if available) for all taxa.  
As reported in the Statistical Analysis section, we applied the GLM not only to the analysis of Pseudomonas 
abundance, but, after checking their distribution, to all bacteria taxa. Moreover, to include possible covariates 
in the analyses, we (i) checked the correlation of clinical-demographic variables (MMSE, BMI, age, and 
gender) with bacteria abundance and (ii) entered clinical-demographic variables in the GLMs according to 
the results of the correlation/association analysis. We apologize for the lack of clarity of the previous version, 
that we have tried to improve by explicitly specifying in the Statistical Analyses and Results sections, that 
we performed GLM analyses for all bacteria taxa. 
The Statistical Analyses section now runs: “…we … applied … Generalized Linear Models (GLM) with log 
link function for the Gamma distributed data for the evaluation of all bacteria taxa across groups” “GLMs 
and ANCOVA were adjusted for MMSE, BMI, age, and gender according to the results of the 
correlation/association analysis”, and the Result section: “The distribution of all bacteria taxa showed a 
significant density mass close to zero and a continuous, right-skewed distribution elsewhere indicating a 
Gamma distribution (p-values of Kolmogorov-Smirnov test for Gamma distributions larger than 0.16 for all 
bacteria taxa). We thus applied GLM models to all bacteria taxa. In keeping with the results of the 
correlation/association analysis, we adjusted all analyses for MMSE, except Pseudomonas aeruginosa’s 
analysis which was adjusted also for BMI.”  
x If it is necessary to select confounders post hoc, then a liberal threshold of p<0.1 or even <0.2 uncorrected 
(between study groups) should be used to select confounders. So what were the thresholds to select potential 
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confounders here?  
The identification and evaluation of potential confounders is a controversial issue, well addressed by 
Rothman KJ and Greenland S (Chapter 8, Modern Epidemiology. 2nd ed. Philadelphia, PA: Lippincott-
Raven; 1998) and Mickey RM and Greenland S (The impact of confounder selection criteria on effect 
estimation. Am J Epidemiol. 1989;129:125–137). The authors suggest that, when the best decision of 
whether or not to adjust is not obvious, the change-in-estimate criterion tends to be superior, though 
significance testing methods can perform acceptably if their significance levels are set much higher than 
conventional level. Tong IS and Lu Y state that “identification and selection of confounding factors need to 
be viewed cautiously. Either the change-in-estimate or significance testing criterion may be implemented in 
the identification of a potential confounder if a study sample is sufficiently large, and both the methods are 
subject to arbitrariness of selecting a cut-off point” (Identification of confounders in the assessment of the 
relationship between lead exposure and child development; Ann Epidemiol. 2001;11:38-45). Pocock et al. 
(Statistics in Medicine. 2002;21:2917-30) noted that a post hoc choice of covariates may not be done 
objectively, leading to estimates that reflect investigator bias.  
More recent literature (see e.g. van Belle et al., 2004, Biostatistics, Chap. 11, Wiley Series in Probability and 
Statistics; and Rosner B., 2011, Fundamentals of Biostatistics, Chap. 13) suggests that substantive 
considerations, based on clinical and/or biological rather than purely statistical evidence, should drive the 
choice of confounders. Accordingly, we based our choice of confounders on literature evidence, and checked 
empirically their confounder status, i.e. the association with both outcome and treatment/exposure. Finally, a 
model-based evaluation of confounders was carried out in terms of goodness of fit indexes (AIC and BIC 
index for Generalized Linear Model) and “parsimony” criterion other than change-in-estimate evaluation.  
We have now provided more details on the above approach in the Statistical Analysis section: “We chose to 
test MMSE, BMI, age and gender as possible confounders based on literature evidence, and checked 
empirically their confounder status, i.e. the association with both outcome and treatment/exposure… Finally, 
a model-based evaluation of confounders was carried out in terms of goodness of fit indexes (AIC and BIC 
index for Generalized Linear Model) and “parsimony” criterion other than change-in-estimate evaluation”. 
x Also the results of these GLMs should be presented (effect sizes, confidence intervals and p values for each 
covariate). 
In linear models, effect sizes (eta-squared or partial eta-squared) are well defined (as portion of explained 
variability expressed in terms of Sum of Squares) and easy to interpret. On the contrary, the non-linearity 
assumption of Generalized Linear Models requires that effect size should be evaluated in terms of variance 
of residuals once the model is fitted. Unfortunately, an appropriate estimate of effect size for a non-gaussian 
response is not straightforward (see e.g. Nakagawa and Schielzeth, 2013, Methods in ecology and evolution, 
4:133-142) and not easy to explain.  
Nevertheless, the p-value of each covariate has now been reported in the Result Section “Candidate bacteria 
taxon abundance in the stools”. 
x In the results, the authors show only fold-change or percent change values. However, also the absolute 
values for abundance (pan bacterial primers were apparently also used) and cytokine levels should be 
presented for each study group, eg in the supplement.  
 
 
Provincia Lombardo - Veneta 
Ordine Ospedaliero di S. Giovanni di Dio – Fatebenefratelli 
 
“CENTRO S. GIOVANNI DI DIO - FATEBENEFRATELLI” 
Istituto di Ricovero e Cura a Carattere Scientifico  
(D.I. 19 Dicembre 1996)  
 
 
 
Via Pilastroni, 4 25125 BRESCIA — Tel. 030.35011 — Fax 030-348255 E-mail centro.sangiovanni.di.dio@fatebenefratelli.it 
Direzione Scientifica — Tel. 030-3501587 Fax 030-3533513 — E-mail irccs.fatebenefratelli@fatebenefratelli.it 
———————————————————————————————————————————————————————————————- 
  Iscrizione Prefettura di Brescia: n. 513 — Registro PG — C.F. e P. IVA 01647730157 
 
In Real Time PCR, the most common and used quantification method is the relative quantification approach 
where target genes are normalized to housekeeping or reference genes. This method does not allow to 
compute absolute values. The values of each target taxon or cytokine have thus been normalized to the 
values of pan bacteria taxa or housekeeping genes respectively. We have already used this commonly and 
widely used method in cytokine gene expression analyses (Hepgul et al., 2016 Neuropsychopharmacology; 
Cattaneo et al., 2013 Int J of neuropsychopharmacology; Di Nicola et al., 2013, Brain Behav Immun; 
Anacker et al. 2013, PNAS).  
x In the previous version the authors stated that subjects also underwent a detailed assessment of concomitant 
medication without showing results and accounting for it in the analysis. Now, the authors do not mention 
any medication assessment anymore. Is the data available or not? Cognitively impaired patients are 
frequently treated with cholinergic drugs that frequently have gastrointestinal side effects and could possibly 
alter microbiota. So, if available, this must be assessed and adjusted if necessary. Otherwise, it must be stated 
that medication effects cannot be ruled out in this study.  
We thank the reviewer for this comment. In the manuscript, on page 8, we mentioned that “Patients 
underwent clinical assessment including medical cognitive and functional history, physical examination 
including collection of height and weight, neurological examination, drug history, mood and behaviour 
assessment, and neuropsychological assessment including the Mini Mental State Exam (MMSE)”. In the 
current version we have added a table (Supplementary Table 2) listing all concomitant medications.  
Cholinergic drugs were taken more frequently by Amy+ than Amy- patients. Although the role of 
cholinergic drugs on gastrointestinal motility is well known, so far there are no data on the effect of these 
drugs on the composition of the microbiota. We have tested the possible association between cholinergic 
drugs and bacteria taxa abundance and failed to find significant associations; thus, we did not include 
cholinergic drugs in the analyses as covariates. The potential effect of cholinergic drugs on GMB 
composition will need to be further addressed in dedicated studies with larger samples.   
x On page 12, the authors report a significant correlation between IL-18 and gender. Gender is a categorical 
variable so probably another test should be used.  
Indeed, we inappropriately used the term “correlation”. In line with what reported in the Statistical Analysis 
section “…parametric tests (ANOVA, t-test and Chi-square) were applied to compare dichotomous and 
continuous variables (demographic and clinical features)”, we used t-test to assess the association between 
IL-8 and gender. We have now changed “correlation” into “association” in the pertinent passage. 
x Regarding the correlations between bacterial abundances and cytokines, unfortunately the bad figure 
reproduction makes evaluation difficult. In my previous review, I was suspicious that correlations were 
biased by a group-difference. Apparently the authors tested correlations now separately for groups. P-values 
for correlations are sensitive to outliers, and all significant correlations need to be visually inspected for their 
plausibility. Therefore, it would be necessary to show the scatter plots, with regression curves and 
confidence intervals separately for each study group and for the whole cohort (in the supplement if 
necessary). Another supportive test would be to make GLMs with the respective cytokines as dependent 
variable and Escherichia, Eubacterium, study group and possibly MMSE and BMI as covariates to see if the 
association with bacteria remains significant. Those results should be reported in detail. 
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As mentioned above, bacterial abundances are skewed variables and they have outliers; for this reason, we 
have adopted Spearman correlation that is used when the assumptions of the Pearson correlation are 
markedly violated (non-gaussianity). Spearman rho does not test the linear, but the monotonic relationship 
between bacterial abundances and cytokine levels. 
As a consequence of the non-linearity of the relationship between bacterial abundances and cytokines, fitting 
a regression line over the scatter plots is not fully appropriate. A more appropriate approach is showing 
curves fitted through a data-driven approach, such as spline function estimation or local polynomial fitted 
curve (see e.g. Cleveland WS, Grosse E, and Shyu WM, 1992, Local regression models. Chapter 8 of 
Statistical Models in S, eds Chambers JM and Hastie TJ, Wadsworth & Brooks/Cole).  
We have modified the scatter plots accordingly by adding the non-parametric fitted curves and we added this 
in the Statistical Analyses Section: For the evaluation of correlations between stool bacteria and blood 
inflammation biomarkers, the algorithm for smoothing scatterplots by robust locally weighted regression 
(Cleveland, Grosse, Shyu, 1992) has been applied to draw the fitted curves. 
x The Abstract must be written more clearly, especially the paragraph dealing with cytokine levels. Is it 
really necessary to show all values in the abstract? The long list of percent values, p, values etc is difficult to 
read, in particular when there is one "Amy+ vs HC" in between that shall probably mean "only Amy+ vs 
HC". Not all abbreviations are explained (e.g. FC). Also the final paragraph should be modified. The authors 
did not study gut microbiota composition and whether it is pro- or anti-inflammatory. Instead they found that 
one putative pro-inflammatory taxon was increased in Amy+ vas May- and HC and one putative anti-
inflammatory taxon was decreased. This does not tell us anything about the global functional output or 
immunological interactions of the whole microbiota. Correlations between the taxa and immune markers are 
very relevant if they remain significant after multiple comparison correction and in adjusted models (see 
above). 
On a general level I would suggest to be cautious with uniformly designating certain bacterial taxa as pro- or 
anti-inflammatory since the effects of bacteria are dynamic and strongly dependent on the milieu. So I would 
suggest to use uniformly an expression like "putative" or "supposedly" when mentioning these activities as 
long as they have not been directly measured. 
We have now modified the abstract following the reviewer’s suggestions.  
It is true that in the current manuscript we have not tested the biologic activities of specific bacteria strains. 
However, their pro- or anti-inflammatory properties have been elucidated in previous studies (Friedland et al., 
2015; De la Fluente et al., 2014; Bruzzese et al., 2014; Cantarel et al., 2015). We have now added the 
cautionary adjective “putative” or “possible” to denote the inflammatory properties of the study bacteria taxa. 
x The authors now use uniformly the word "species" for the bacteria that they investigated. However, 
Escherichia/Shigella is a "genus". The easiest way would be to use the term taxon / taxa since this applies to 
all taxonomic levels. 
We thank the reviewer for this suggestion. We have now revised all the manuscript and used the term taxon 
or taxa when appropriate.  
x In the MM section the authors still use the term "Pan Bacteria species" this should be probably replaced by 
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"Pan bacteria primers".  (?) 
We have now replaced "Pan Bacteria species" with "Pan bacteria primers".   
x In Figure 1 the black and grey columns are named as Abeta-negative, I suppose one of them should be 
positive. 
We thank the reviewer and we apologise for the oversight. We have now corrected the legend in the graph. 
 
 
Reviewer #3 
x The authors have adequately addressed my comments. One note: Figure 1 has both conditions labelled Ab-, 
whereas the black bars should be Ab+. 
We are happy we have been able to address all the reviewer’s issues. Figure 1 has now been modified. 
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Reviewers' comments to revision 1 
 
 
Reviewer #2 
x The manuscript has considerably improved during this first revision and the authors have improved their 
statistical analysis. Also healthy controls have been included. Unfortunately figure reproduction in the PDF 
is very bad so it is difficult to evaluate the figures in detail. 
We are sorry to read that this reviewer could not evaluate the figures in detail. We have taken the freedom to 
download ourselves the PDF file from Elsevier’s Editorial System. By clicking the link “download high 
resolution figure” at the top of each figure, we could easily download the high resolution version of the 
figures.  
x However, to me, the parts of the presentation of the results is difficult to follow and I would suggest to 
include more supportive material in the supplement. Some native English language editing support could be 
worthwhile. There are still some statistical aspects that need to be clarified. The authors now use GLMs with 
a gamma distribution for confounder adjustment which is appropriate. However, they post hoc selected 
confounders based on correlations between taxa and clinical variables. Apparently this led them to use GLM 
only for Pseudomonas? Since in this case not many taxa have been studied and also the number of clinical 
variables is limited, it would be preferable to use such GLM adjustment (using eg, MMSE and BMI, and 
medication if available) for all taxa.  
As reported in the Statistical Analysis section, we applied the GLM not only to the analysis of Pseudomonas 
abundance, but, after checking their distribution, to all bacteria taxa. Moreover, to include possible covariates 
in the analyses, we (i) checked the correlation of clinical-demographic variables (MMSE, BMI, age, and 
gender) with bacteria abundance and (ii) entered clinical-demographic variables in the GLMs according to 
the results of the correlation/association analysis. We apologize for the lack of clarity of the previous version, 
that we have tried to improve by explicitly specifying in the Statistical Analyses and Results sections, that 
we performed GLM analyses for all bacteria taxa. 
The Statistical Analyses section now runs: “…we … applied … Generalized Linear Models (GLM) with log 
link function for the Gamma distributed data for the evaluation of all bacteria taxa across groups” “GLMs 
and ANCOVA were adjusted for MMSE, BMI, age, and gender according to the results of the 
correlation/association analysis”, and the Result section: “The distribution of all bacteria taxa showed a 
significant density mass close to zero and a continuous, right-skewed distribution elsewhere indicating a 
Gamma distribution (p-values of Kolmogorov-Smirnov test for Gamma distributions larger than 0.16 for all 
bacteria taxa). We thus applied GLM models to all bacteria taxa. In keeping with the results of the 
correlation/association analysis, we adjusted all analyses for MMSE, except Pseudomonas aeruginosa’s 
analysis which was adjusted also for BMI.”  
*Response to Reviewers
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x If it is necessary to select confounders post hoc, then a liberal threshold of p<0.1 or even <0.2 uncorrected 
(between study groups) should be used to select confounders. So what were the thresholds to select potential 
confounders here?  
The identification and evaluation of potential confounders is a controversial issue, well addressed by 
Rothman KJ and Greenland S (Chapter 8, Modern Epidemiology. 2nd ed. Philadelphia, PA: Lippincott-
Raven; 1998) and Mickey RM and Greenland S (The impact of confounder selection criteria on effect 
estimation. Am J Epidemiol. 1989;129:125–137). The authors suggest that, when the best decision of 
whether or not to adjust is not obvious, the change-in-estimate criterion tends to be superior, though 
significance testing methods can perform acceptably if their significance levels are set much higher than 
conventional level. Tong IS and Lu Y state that “identification and selection of confounding factors need to 
be viewed cautiously. Either the change-in-estimate or significance testing criterion may be implemented in 
the identification of a potential confounder if a study sample is sufficiently large, and both the methods are 
subject to arbitrariness of selecting a cut-off point” (Identification of confounders in the assessment of the 
relationship between lead exposure and child development; Ann Epidemiol. 2001;11:38-45). Pocock et al. 
(Statistics in Medicine. 2002;21:2917-30) noted that a post hoc choice of covariates may not be done 
objectively, leading to estimates that reflect investigator bias.  
More recent literature (see e.g. van Belle et al., 2004, Biostatistics, Chap. 11, Wiley Series in Probability and 
Statistics; and Rosner B., 2011, Fundamentals of Biostatistics, Chap. 13) suggests that substantive 
considerations, based on clinical and/or biological rather than purely statistical evidence, should drive the 
choice of confounders. Accordingly, we based our choice of confounders on literature evidence, and checked 
empirically their confounder status, i.e. the association with both outcome and treatment/exposure. Finally, a 
model-based evaluation of confounders was carried out in terms of goodness of fit indexes (AIC and BIC 
index for Generalized Linear Model) and “parsimony” criterion other than change-in-estimate evaluation.  
We have now provided more details on the above approach in the Statistical Analysis section: “We chose to 
test MMSE, BMI, age and gender as possible confounders based on literature evidence, and checked 
empirically their confounder status, i.e. the association with both outcome and treatment/exposure… Finally, 
a model-based evaluation of confounders was carried out in terms of goodness of fit indexes (AIC and BIC 
index for Generalized Linear Model) and “parsimony” criterion other than change-in-estimate evaluation”. 
x Also the results of these GLMs should be presented (effect sizes, confidence intervals and p values for each 
covariate). 
In linear models, effect sizes (eta-squared or partial eta-squared) are well defined (as portion of explained 
variability expressed in terms of Sum of Squares) and easy to interpret. On the contrary, the non-linearity 
assumption of Generalized Linear Models requires that effect size should be evaluated in terms of variance 
of residuals once the model is fitted. Unfortunately, an appropriate estimate of effect size for a non-gaussian 
response is not straightforward (see e.g. Nakagawa and Schielzeth, 2013, Methods in ecology and evolution, 
4:133-142) and not easy to explain.  
Nevertheless, the p-value of each covariate has now been reported in the Result Section “Candidate bacteria 
taxon abundance in the stools”. 
x In the results, the authors show only fold-change or percent change values. However, also the absolute 
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values for abundance (pan bacterial primers were apparently also used) and cytokine levels should be 
presented for each study group, eg in the supplement.  
In Real Time PCR, the most common and used quantification method is the relative quantification approach 
where target genes are normalized to housekeeping or reference genes. This method does not allow to 
compute absolute values. The values of each target taxon or cytokine have thus been normalized to the 
values of pan bacteria taxa or housekeeping genes respectively. We have already used this commonly and 
widely used method in cytokine gene expression analyses (Hepgul et al., 2016 Neuropsychopharmacology; 
Cattaneo et al., 2013 Int J of neuropsychopharmacology; Di Nicola et al., 2013, Brain Behav Immun; 
Anacker et al. 2013, PNAS).  
x In the previous version the authors stated that subjects also underwent a detailed assessment of concomitant 
medication without showing results and accounting for it in the analysis. Now, the authors do not mention 
any medication assessment anymore. Is the data available or not? Cognitively impaired patients are 
frequently treated with cholinergic drugs that frequently have gastrointestinal side effects and could possibly 
alter microbiota. So, if available, this must be assessed and adjusted if necessary. Otherwise, it must be stated 
that medication effects cannot be ruled out in this study.  
We thank the reviewer for this comment. In the manuscript, on page 8, we mentioned that “Patients 
underwent clinical assessment including medical cognitive and functional history, physical examination 
including collection of height and weight, neurological examination, drug history, mood and behaviour 
assessment, and neuropsychological assessment including the Mini Mental State Exam (MMSE)”. In the 
current version we have added a table (Supplementary Table 2) listing all concomitant medications.  
Cholinergic drugs were taken more frequently by Amy+ than Amy- patients. Although the role of 
cholinergic drugs on gastrointestinal motility is well known, so far there are no data on the effect of these 
drugs on the composition of the microbiota. We have tested the possible association between cholinergic 
drugs and bacteria taxa abundance and failed to find significant associations; thus, we did not include 
cholinergic drugs in the analyses as covariates. The potential effect of cholinergic drugs on GMB 
composition will need to be further addressed in dedicated studies with larger samples.   
x On page 12, the authors report a significant correlation between IL-18 and gender. Gender is a categorical 
variable so probably another test should be used.  
Indeed, we inappropriately used the term “correlation”. In line with what reported in the Statistical Analysis 
section “…parametric tests (ANOVA, t-test and Chi-square) were applied to compare dichotomous and 
continuous variables (demographic and clinical features)”, we used t-test to assess the association between 
IL-8 and gender. We have now changed “correlation” into “association” in the pertinent passage. 
x Regarding the correlations between bacterial abundances and cytokines, unfortunately the bad figure 
reproduction makes evaluation difficult. In my previous review, I was suspicious that correlations were 
biased by a group-difference. Apparently the authors tested correlations now separately for groups. P-values 
for correlations are sensitive to outliers, and all significant correlations need to be visually inspected for their 
plausibility. Therefore, it would be necessary to show the scatter plots, with regression curves and 
confidence intervals separately for each study group and for the whole cohort (in the supplement if 
necessary). Another supportive test would be to make GLMs with the respective cytokines as dependent 
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variable and Escherichia, Eubacterium, study group and possibly MMSE and BMI as covariates to see if the 
association with bacteria remains significant. Those results should be reported in detail. 
As mentioned above, bacterial abundances are skewed variables and they have outliers; for this reason, we 
have adopted Spearman correlation that is used when the assumptions of the Pearson correlation are 
markedly violated (non-gaussianity). Spearman rho does not test the linear, but the monotonic relationship 
between bacterial abundances and cytokine levels. 
As a consequence of the non-linearity of the relationship between bacterial abundances and cytokines, fitting 
a regression line over the scatter plots is not fully appropriate. A more appropriate approach is showing 
curves fitted through a data-driven approach, such as spline function estimation or local polynomial fitted 
curve (see e.g. Cleveland WS, Grosse E, and Shyu WM, 1992, Local regression models. Chapter 8 of 
Statistical Models in S, eds Chambers JM and Hastie TJ, Wadsworth & Brooks/Cole).  
We have modified the scatter plots accordingly by adding the non-parametric fitted curves and we added this 
in the Statistical Analyses Section: For the evaluation of correlations between stool bacteria and blood 
inflammation biomarkers, the algorithm for smoothing scatterplots by robust locally weighted regression 
(Cleveland, Grosse, Shyu, 1992) has been applied to draw the fitted curves. 
x The Abstract must be written more clearly, especially the paragraph dealing with cytokine levels. Is it 
really necessary to show all values in the abstract? The long list of percent values, p, values etc is difficult to 
read, in particular when there is one "Amy+ vs HC" in between that shall probably mean "only Amy+ vs 
HC". Not all abbreviations are explained (e.g. FC). Also the final paragraph should be modified. The authors 
did not study gut microbiota composition and whether it is pro- or anti-inflammatory. Instead they found that 
one putative pro-inflammatory taxon was increased in Amy+ vas May- and HC and one putative anti-
inflammatory taxon was decreased. This does not tell us anything about the global functional output or 
immunological interactions of the whole microbiota. Correlations between the taxa and immune markers are 
very relevant if they remain significant after multiple comparison correction and in adjusted models (see 
above). 
On a general level I would suggest to be cautious with uniformly designating certain bacterial taxa as pro- or 
anti-inflammatory since the effects of bacteria are dynamic and strongly dependent on the milieu. So I would 
suggest to use uniformly an expression like "putative" or "supposedly" when mentioning these activities as 
long as they have not been directly measured. 
We have now modified the abstract following the reviewer’s suggestions.  
It is true that in the current manuscript we have not tested the biologic activities of specific bacteria strains. 
However, their pro- or anti-inflammatory properties have been elucidated in previous studies (Friedland et al., 
2015; De la Fluente et al., 2014; Bruzzese et al., 2014; Cantarel et al., 2015). We have now added the 
cautionary adjective “putative” or “possible” to denote the inflammatory properties of the study bacteria taxa. 
x The authors now use uniformly the word "species" for the bacteria that they investigated. However, 
Escherichia/Shigella is a "genus". The easiest way would be to use the term taxon / taxa since this applies to 
all taxonomic levels. 
We thank the reviewer for this suggestion. We have now revised all the manuscript and used the term taxon 
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or taxa when appropriate.  
x In the MM section the authors still use the term "Pan Bacteria species" this should be probably replaced by 
"Pan bacteria primers".  (?) 
We have now replaced "Pan Bacteria species" with "Pan bacteria primers".   
x In Figure 1 the black and grey columns are named as Abeta-negative, I suppose one of them should be 
positive. 
We thank the reviewer and we apologise for the oversight. We have now corrected the legend in the graph. 
 
 
Reviewer #3 
x The authors have adequately addressed my comments. One note: Figure 1 has both conditions labelled Ab-, 
whereas the black bars should be Ab+. 
We are happy we have been able to address all the reviewer’s issues. Figure 1 has now been modified. 
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Abstract 
The pathway leading from beta-amyloid deposition to cognitive impairment is believed to be a 
cornerstone of the pathogenesis of Alzheimer’s disease (AD). However, what drives amyloid build-up in 
sporadic non-genetic cases of AD is still unknown. AD brains feature an inflammatory reaction around 
amyloid plaques, and a specific subset of the gut microbiota (GMB) may promote brain inflammation.  
We investigated the possible role of the GMB in AD pathogenesis by studying the association of brain 
amyloidosis with (i) GMB taxa with pro- and anti-inflammatory activity, and (ii) peripheral inflammation 
in cognitively impaired patients. 
We measured the stool abundance of selected bacterial GMB taxa (Escherichia/Shigella, Pseudomonas 
aeruginosa, Eubacterium rectale, Eubacterium hallii, Faecalibacterium prausnitzii and Bacteroides 
fragilis) and the blood expression levels of cytokines (pro-inflammatory cytokines: CXCL2, CXCL10, 
IL-1β, IL-6, IL-18, IL-8, NLRP3, TNF-α; anti-inflammatory cytokines: IL-4, IL-10, IL-13) in cognitively 
impaired patients with (n=40, Amy+) and with no brain amyloidosis (n=33, Amy-), and also in a group of 
controls (n=10, no brain amyloidosis and no cognitive impairment, HC). 
Amy+ patients showed higher levels of pro-inflammatory cytokines (IL-6, CXCL2, NLRP3 and IL-1β) 
compared to both controls and to Amy- patients. A reduction of the anti-inflammatory cytokine IL-10 was 
observed in Amy+ versus Amy-. Amy+ showed lower abundance of Eubacterium rectale and higher 
abundance of Escherichia/Shigella as compared to both HC (Fold Change, FC=-9.6, p<0.001 and 
FC=+12.8, p<0.001, respectively) and to Amy- (FC=-7.7, p<0.001 and FC=+7.4, p=0.003). A positive 
correlation was observed between pro-inflammatory cytokines IL-1β, NLRP3 and CXCL2 with 
abundance of the inflammatory bacteria taxon Escherichia/Shigella (rho=0.60, p<0.001; rho=0.57, 
p<0.001; and rho=0.30, p=0.007, respectively) and a negative correlation with the anti-inflammatory 
Eubacterium rectale (rho=-0.48, p<0.001; rho=-0.25, p=0.024; rho=-0.49, p<0.001).  
Our data indicate that an increase in the abundance of a pro-inflammatory GMB taxon, 
Escherichia/Shigella, and a reduction in the abundance of an anti-inflammatory taxon, Eubacterium 
rectale, are possibly associated with a peripheral inflammatory state in patients with cognitive impairment 
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and brain amyloidosis. A possible causal relation between GMB-related inflammation and amyloidosis 
deserves further investigation. 
Key words: cognitive impairment, brain amyloidosis, inflammation, gut microbiota, neurodegeneration 
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Introduction 
Neurodegenerative disorders, including Alzheimer's disease (AD), are characterized by the accumulation 
in the brain of neurotoxic proteins. In AD, these are β-amyloid (Aβ) and hyper-phosphorylated tau, 
representing the major components of extracellular senile plaques and intracellular neurofibrillary tangles, 
respectively. The common feature of these proteins is the loss of their physiologic activity and the gain of 
toxic properties, promoting neurodegeneration. Aβ is widely believed to be key in AD pathophysiology 
(Jack et al, 2013). In non-genetic cases of AD, the pathophysiological mechanisms of Aβ deposition and 
the ensuing neurodegeneration and cognitive symptoms remain to be elucidated, but neuroinflammation 
seems to play a key role (Heppner et al, 2015). Indeed, in addition to plaques and tangles, AD patients 
feature central inflammation, mediated by activated microglia, reactive astrocytes and complement 
activation, that have been especially observed in the vicinity of amyloid plaques and even in the early 
stages of AD (Heppner et al., 2015; Clark et al., 2015; Heneka et al., 2015; Latta et al., 2015; Stoeck et 
al., 2014). Enhanced inflammation occurs also in body fluids of AD patients, such as cerebrospinal fluid 
(CSF) and blood (Vom Berg et al., 2012; Kauwe et al., 2014; Nascimento et al., 2014; Monson et al., 
2014). 
The increased interest in the complex network of inflammatory mediators and the immune system has 
allowed to identify a growing number of pro-inflammatory molecules involved in central nervous system 
(CNS) disorders, such as Interleukin (IL)-6, Tumor Necrosis Factor-alpha (TNF-α) and the 
inflammasome complex (NLRP3). These have been found associated with cognitive impairment and AD 
pathology (Leung et al., 2013; Ray et al., 2007; Soares et al., 2012a; Doecke et al., 2012; Chen et al., 
2015; Tan et al., 2013). However, the pathophysiological cascade linking inflammation with Aβ 
deposition is still unknown (Heppner et al., 2015). Some recent observations indicate that a specific 
subset of the gut microbiota (GMB) can drive neuroinflammation in rodents (Palm et al., 2015; Petra et 
al., 2015; Erny et al., 2015) and affect brain function and behaviour in rodents and humans (Li et al., 
2009; Diaz et al., 2011; Bercik et al., 2011).  
Alterations of GMB composition have been observed in multiple sclerosis (MS) and Parkinson’s disease 
(PD), conditions also featuring neuroinflammation and protein misfolding. Indeed, the removal of GMB 
in animal models of multiple sclerosis prevents the development of relapsing-remitting demyelination 
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(Berer et al., 2011) and oral ingestion of probiotics attenuates neuroinflammation (Toumi et al., 2014; 
Luo et al., 2014). In Parkinson’s disease, the evidence is even stronger. The deposition of alpha (α)-
synuclein, the underlying molecular pathology, has been found both in the digestive tract and enteric 
nervous system, already in the early phases of the disease (Del Tredici et al., 2010; Lebouvier et al., 2010; 
Goedert et al., 2013). Moreover, the gut mucosa of Parkinsonian patients shows increased permeability, 
signs of inflammation and invasion of coliform bacteria (Forsyth et al., 2011), and hosts a peculiar GMB 
composition, characterized by decreased abundance of Prevotellaceae and an increase in 
Enterobacteriaceae, which are also related to the severity of illness (Scheperjans et al., 2015). 
Importantly, enhanced inflammation, as a consequence of alterations in GMB composition, has been 
implicated in the initiation of α-synuclein misfolding (Olanow et al., 2014). 
To our knowledge, no evidence of GMB alterations has been reported in AD patients yet; however, it has 
been recently suggested that bacterial endotoxins may play a key role in the inflammatory and 
pathological processes associated with amyloidosis and AD (Asti & Gioglio, 2014; Vom Berg et al., 
2012), as bacterial components, such as endotoxins, have been found within the typical senile plaque 
lesions of the AD brain (Asti & Gioglio, 2014; Schwartz  et al., 2013).  
The aim of this study was to test, in elder patients with cognitive impairment, the association between 
brain amyloidosis and: (i) candidate GMB taxa with known inflammatory activity (pro-inflammatory: 
Escherichia/Shigella and Pseudomonas aeruginosa; anti-inflammatory: Eubacterium rectale, 
Eubacterium hallii, Faecalibacterium prausnitzii, and Bacteroides fragilis) (Friedland et al., 2015; De la 
Fluente et al., 2014; Bruzzese et al., 2014; Cantarel et al., 2015); (ii) peripheral inflammation markers 
implicated in the pathogenesis of AD (pro-inflammatory cytokines: CXCL2, CXCL10, IL-1β, IL-6, IL-
18, IL-8, NLRP3, TNF-α; anti-inflammatory cytokines: IL-4, IL-10, IL-13) (Leung et al., 2013; Ray et 
al., 2007; Doecke et al., 2012; Chen et al., 2015; Tan et al., 2013;Soares et al., 2012a).  
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Methods 
Study Design and Patients Description 
The patients have been recruited from a larger study in 18 memory clinics in Eastern Lombardy, Italy, 
aiming to assess the added value of amyloid imaging in the clinical work-up of patients with cognitive 
complaints (the INDIA-FBP study – Incremental Diagnostic value of Florbetapir Amyloid Imaging) 
(http://www.centroalzheimer.org/sito/ip_lilly.php). Patients coming to observation with cognitive 
impairment and AD as a possible etiology were offered, on top and at the end of their routine clinical 
assessment, amyloid PET with 18F-Florbetapir. Two hundreds and forty-one patients and twenty-six 
cognitively healthy elders, mostly patients’ spouses, were recruited between August 2013 and December 
2014. All patients underwent routine diagnostic work-up as prescribed by their memory clinic specialist, 
which in all cases included clinical and neuropsychological assessment. Some patients underwent 
structural brain MRI and CSF analyses for Aβ and total and phosphorylated tau levels detection. The local 
Ethics Committee at IRCCS San Giovanni di Dio – Fatebenefratelli gave ethical approval of the present 
as an embedded study into INDIA-FBP (authorization n. 57/2014). Accepting patients signed an ad hoc 
informed consent.  
After completion of the INDIA-FBP procedures, 150 patients and controls who were not under antibiotic 
and anti-inflammatory treatment over the past 3 months or had been diagnosed with major depression or 
other psychiatric disorders were proposed to contribute samples of stools and blood for the current study. 
Patients were defined as cognitively impaired in the case they matched these criteria: i) presence of 
cognitive complaints reported by patients or proxy or by the doctor; ii) presence of no intracranial 
metabolic or psychiatric causes of cognitive impairments; iii) presence of abnormal scores in two or more 
cognitive tests, and iv) history of progression of cognitive symptoms. Ten cognitively healthy amyloid 
negative controls (HC), 40 cognitively impaired Amyloid-positive patients (Amy+), and 33 cognitively 
impaired Amyloid-negative patients (Amy-) gave their consent to participate to the study and donate 
blood and stool samples.  
Patients underwent clinical assessment including medical cognitive and functional history, physical 
examination including collection of height and weight, neurological examination, drug history, mood and 
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behaviour assessment, and neuropsychological assessment including the Mini Mental State Exam 
(MMSE) (Folstein et al., 1975). Body-mass index (BMI) was defined as height/weight2 and measured in 
cm/kg2. The neuropsychological battery consisted of tests tapping verbal and non-verbal learning, 
immediate memory, abstract thinking, visuospatial planning, constructional apraxia, verbal fluency, and 
comprehension. Medial temporal atrophy and subcortical cerebrovascular disease were assessed with 
validated and largely used visual rating tools (the Medial Temporal Atrophy – MTA (Scheltens et al., 
1993) and the Age-Related White Matter Changes – ARWMC – scales (Wahlund et al., 2001), ranging 
from 0 to 4 and 0 to 30 respectively, where 0 means no abnormal changes. Neuropsychological test scores 
have been reported in Supplementary Table 1 and current medication in Supplementary Table 2. 
Amyloid PET  
Patients underwent amyloid PET at the Nuclear Medicine Service of Spedali Civili and Fondazione 
Poliambulanza in Brescia with GE Discovery 690 and Siemens Biograph 40m PET-CT scanners, 
respectively. PET was a 10-minute (two 5-minutes frames) 3-Dimensional acquisition, 50 minutes after 
the injection of an intravenous bolus of 370 MBq (10 mCi) of 18F-Florbetapir (Clark et al., 2012). 
Attenuation correction was calculated based on the co-acquired CT. PET images were reconstructed onto 
a 128x128 matrix with slice thickness of 3 to 3.3 mm, using a 2-3 mm Gaussian post reconstruction filter. 
Subjects were categorised into Amy+ and Amy- following a validated procedure 
(http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Peripheraland
CentralNervousSystemDrugsAdvisoryCommittee/UCM240266.pdf”). PET exemplars from a HC, an 
Amy+, and an Amy- participant can be found in Supplementary Material (see Supplementary Figure 1). 
Amyloid positivity was visually rated independently by two nuclear physicians, and blind to patients’ 
clinical information. A third expert was in charge of adjudicating discordant cases, which amounted to 
12% of the total.  
Stool sample collection and DNA isolation  
Stool samples were collected by participants at their own home in a sterile plastic cup, stored at -20°C, 
and delivered to IRCCS Fatebenefratelli Institute within the following 24 hours, where they were stored at 
-20°C until processing. Microbial DNA was extracted three times in three different sections from each 
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patient’s stool taking 200 mg of stool per time, using the QIAamp DNA Stool Mini Kit (Qiagen) and 
according to manufacturer’s instructions, with the additional glass-bead beating steps on a Mini-
beadbeater (FastPrep; Thermo Electron Corp.). DNA samples coming from the same patients were 
subsequently tested as technical triplicates. DNA was quantified using a NanoDrop ND-1000 
spectrophotometer and DNA integrity and size were assessed by 1.0% agarose gel electrophoresis on gels 
containing 0.5mg/mL ethidium bromide. DNA samples were then stored at -20°C until subsequent 
analyses.  
Bacterial DNA quantification in stools  
The abundance analyses of the selected bacterial taxa (Escherichia/Shigella, Pseudomonas aeruginosa, 
Eubacterium rectale, Eubacterium hallii, Faecalibacterium prausnitzii and Bacteroides fragilis) were 
carried out using the Microbial DNA qPCR Assay kit (Qiagen, Crawley, UK) and a StepOnePlus 
instrument (Applied Biosystems, Foster City, CA, USA), according to manufacturer’s instructions. Fifty 
nanograms of total DNA were used for each sample. Pan Bacteria primers designed to detect the broadest 
possible collection of bacteria hosted in the human gut were measured together with candidate taxa to 
normalize the abundance of each candidate bacterial taxon.  
The kits for the detection of the above mentioned taxa do not provide the primer sequences, and we here 
include the code number for each assay (Pan Bacteria 1: BPCL00360AR; Escherichia/Shigella: 
BPID00146AR; P.. aeruginosa: BPID00288AR; E. rectale: BPID00149AR; E. hallii: BPID00147AR; F. 
prausnitzii: BPID00154AR; B. fragilis: BPID00146AR). 
The abundance of each taxon was then calculated according to the comparative Ct method (-∆∆Ct 
method) (Schmittgen et al., 2008) and following the Microbial DNA qPCR Assay kit protocol 
(https://www.qiagen.com/us/products/catalog/assay-technologies/real-time-pcr-and-rt-pcr-
reagents/microbial-dna-qpcr-assay-kits/) where the control subjects (HC) have been used as reference 
group.  When comparing groups, this method allows to obtain a Fold Change (FC) value of differences 
for each candidate bacteria taxon.   
Gene expression analyses of inflammatory molecules in blood 
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Isolation of total RNA was performed using the PAXgene blood miRNA kit, according to the 
manufacturer’s recommended protocol (Qiagen). RNA quantity and quality were assessed by evaluation 
of the A260/280 and A260/230 ratios, using a Nanodrop spectrophotometer (NanoDrop Technologies, 
USA) and RNA samples were then kept at -80°C until their processing for gene expression analyses. 
Gene expression levels were analysed by a 384 wells qRT-PCR instrument (Bio-Rad Instrument), using 
the iScriptTM one-step RT-PCR kit for probes (Bio-Rad Laboratories) and Applied BioSystem Assays 
(Gene Expression Assays: CXCL2, CXCL10, IL-1β, IL-6, IL-18, IL-8, NLRP3, TNF-α, IL-4, IL-10, IL-
13) as previously reported (Cattaneo et al., 2013). Samples were run in triplicates and each target gene 
was normalized to the expression of three housekeeping genes (HK), glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), β-2-microglobulin (B2M) and β-actin. All the assays for the gene expression 
analyses of both target and HK genes were purchased from Life Technologies (Monza, Italy). For each 
sample, 50 ng of RNA were added to the Real Time PCR Mix. Thermal cycling was initiated with an 
incubation at 50°C for 10 minutes, followed by 5 minutes at 95°C. After this initial step, 39 cycles of 
PCR were performed. Each PCR cycle consisted of heating the samples at 95°C for 10 seconds to enable 
the melting process and then for 30 seconds at 60°C for the annealing and extension reactions. The 
expression of target genes was calculated according to the Ct method (-∆∆Ct method) (Schmittgen et al., 
2008), where the control subjects (HC) have been used as reference group. We thus obtained, as output, a 
Relative Expression Ratio (R) value for each cytokine in each sample.  
Statistical analysis 
Parametric (ANOVA, t-test and Chi-square) and non-parametric (Mann-Whitney) tests were applied to 
compare dichotomous and continuous variables (demographic and clinical features) between the study 
groups or other variables. Pearson linear correlation (r) and Spearman rank correlation (rho) were used for 
Gaussian and non-Gaussian distributed variables respectively, to evaluate correlations between 
demographic and clinical variables. For the evaluation of correlations between stool bacteria and blood 
inflammation biomarkers, the algorithm for smoothing scatterplots by robust locally weighted regression 
(Cleveland et al., 1992) was applied to draw the fitted curves. 
We chose to test MMSE, BMI, age and gender as possible confounders based on literature evidence, and 
checked empirically their confounder status, i.e. the association with both outcome and 
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treatment/exposure. Moreover, we have also tested the association between cholinergic drugs and bacteria 
taxa, based on the notion that these drugs exert an effect on intestinal motility.  
Finally, a model-based evaluation of confounders was carried out in terms of goodness of fit indexes 
(AIC and BIC index for Generalized Linear Model) and “parsimony” criterion other than change-in-
estimate evaluation”. 
The normality assumption of cytokine blood levels and bacteria taxa were evaluated by Tukey boxplot 
(with 1.5 interquartile range, IQR) and QQ-plot inspection and tested by Shapiro-Wilk and Kolmogorov-
Smirnov tests. According to the distribution of dependent variables (bacteria taxa abundances or 
cytokines mRNA levels) we then applied: (i) Generalized Linear Models (GLM), with log link function 
for the Gamma distributed data, for the evaluation of all bacteria taxa across groups; and (ii) Analysis of 
Covariance (ANCOVA) models for cytokine blood levels. GLM and ANCOVA were adjusted for 
MMSE, BMI, age, and gender according to the results of the correlation/association analysis.  
Post-hoc group comparisons were evaluated by Bonferroni adjustment. Statistical significance was set at 
p<0.05. Statistical analyses were performed by SPSS version 22.0, and R: A language and environment 
for statistical computing, version 3.2.5, R Foundation for Statistical Computing, Vienna, Austria. 
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Results 
Clinical sample description 
The three groups were similar for age, gender, and BMI. Amy+ patients had lower cognitive 
performances than both Amy- and HC (Table 1). Both neurodegeneration in the medial temporal lobe and 
microvascular white matter changes were similar in Amy+ and Amy-. Indeed, Amy- and Amy+ patients 
did not show any significant difference on medial temporal atrophy (Scheltens' scale: mean ± SD 1.8±1.1 
and 2.0±0.8; p=0.670) nor white matter changes (ARWMC scale: mean ± SD 2.5±3.1 and 1.8±2.2; 
p=0.520).  
Candidate bacteria taxon abundance in the stools 
First, we assessed the association between abundance of all bacteria taxa with demographic and clinical 
(MMSE, BMI, age gender, assumption of cholinergic drug) variables. We found a significant association 
only between Pseudomonas aeruginosa and BMI (rho=0.41, p=0.037).  Thus, BMI was included, together 
with the MMSE, as a covariate in the GLM with Pseudomonas aeruginosa as dependent variable. No 
correlations with age (p values of Spearman correlation >0.097) as well as no associations (evaluated by 
Mann-Whitney tests) with gender (p>0.100) were found for all bacteria taxa. The assumption of 
cholinergic drugs was differentially distributed between Amy+ and Amy- patients (Chi-squared p<0.001), 
but the association with bacteria taxa abundances was not significant (p>0.050) for all bacteria taxa.  
The distribution of all bacteria taxa showed a significant density mass close to zero and a continuous, 
right-skewed distribution elsewhere indicating a Gamma distribution (p-values of Kolmogorov-Smirnov 
test for Gamma distributions larger than 0.16 for all bacteria taxa). We thus applied GLM models to all 
bacteria taxa. In keeping with the results of the correlation/association analysis, we adjusted all analyses 
for MMSE, except Pseudomonas aeruginosa’s analysis which was adjusted also for BMI. 
In Amy+ we found a specific pattern of alterations in bacteria taxa abundance when compared to HC and 
to Amy+. In particular, Amy+ showed lower abundance of Eubacterium rectale and higher abundance of 
Escherichia/Shigella as compared to both HC (FC=-9.6, p<0.001 and FC=+12.8, p<0.001; MMSE p= 
0.029 and 0.104 respectively) and to Amy- (FC=-7.7, p<0.001 and FC=+7.4, p=0.003; MMSE p= 0.053 
and 0.205 respectively). Moreover, Amy+ showed lower abundance of Bacteroides fragilis than HC 
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(FC=-24.5, p=0.032; MMSE p=0.369). No difference in the abundance of the other bacteria taxa was 
observed (Figure 1).  
Expression of inflammation biomarkers in the blood 
The distribution of gene expression values was Gaussian for all cytokines (p-values of Kolmogorov-
Smirnov test for normal distributions always larger than 0.100). We assessed possible associations 
between the demographic variables age, gender and BMI, with the levels of the cytokines and we found a 
significant correlation between NLRP3 and age (r=0.27, p=0.013), between IL-6 and age (r=-0.24, 
p=0.032) and between IL-18 and gender (r=0.25, p=0.022). Thus, in addition to MMSE, we have also 
included age and/or gender as covariates, whenever necessary, in the analyses.  
As shown in Figure 2, Amy+ showed a specific pattern of higher levels of four pro-inflammatory 
cytokines (NLRP3, CXCL2, IL-6 and IL-1β), as their levels were different compared to both HC and 
Amy-. In particular, we found significantly increased expression of NLRP3, CXCL2, IL-6 and IL-1β in 
Amy+ versus HC (+22%, p=0.030; +36%, p<0.001; +22%, p=0.030; and +40%, p=0.004, respectively) 
and versus Amy- (+19%, p=0.006; +24%, p<0.001; +32% p<0.001; +22%, p=0.040). 
Amy+ and Amy- showed a similar pattern of increased expression of TNF-α when compared to HC 
(+29%, p<0.001 and +31%, p<0.001 respectively). With regard to anti-inflammatory cytokines, Amy+ 
patients showed a significantly reduced expression of IL-10, but only compared to Amy- (-25%, 
p=0.007); no significant difference in the expression levels of CXCL10, IL-18, IL-8, IL-4 and IL-13 was 
observed across groups (all p>0.05). 
Correlation between stool bacteria and blood inflammation biomarkers 
We performed Spearman correlation analyses between cytokines and bacteria strains focussing on 
cytokines and strains whose pattern was significantly different in Amy+ patients both versus HC and 
Amy-.  
In particular, we correlated the blood levels of the cytokines CXCL2, IL-6, NLRP3, IL-1β, IL-10 with the 
stool abundance of Escherichia/Shigella and Eubacterium rectale. We found a positive correlation 
between the pro-inflammatory cytokines IL-1β, NLRP3 and CXCL2 with abundance of 
Escherichia/Shigella (rho=0.60, p<0.001; rho=0.57, p<0.001; rho=0.30, p=0.007, respectively) (Figure 
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3). A negative correlation was observed between blood levels of the pro-inflammatory cytokines IL-1β, 
NLRP3 and CXCL2 with stool abundance of anti-inflammatory bacteria Eubacterium rectale (rho=-0.48, 
p<0.001; rho=-0.25, p=0.024; rho=-0.49, p<0.001, respectively) and a positive correlation between IL-10 
blood levels and Eubacterium rectale (rho=0.30, p=0.030) (Figure 4). 
Most of the correlations hold significant also when Amy+ and Amy- were investigated separately. In 
particular, we found a positive correlation between the blood levels of IL-1β and NLRP3 with 
Escherichia/Shigella in both Amy+ (rho=0.34, p=0.032 and rho=0.65, p<0.001, respectively) and Amy- 
(rho=0.45, p=0.009 and rho=0.47, p=0.007), and a negative correlation between the levels of IL-1β and 
CXCL2 with Eubacterium rectale in Amy +(rho=-0.37, p=0.020 and rho=-0.32, p=0.040) and Amy- 
(rho=-0.43, p=0.014 and rho=-0.37, p=0.040). 
Importantly, when we evaluated the MMSE contribution in these analyses (through GLM with MMSE as 
covariate), we found no influence on the main effect for all tested correlations (all p>0.05). 
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Discussion 
In the present study we have investigated the association of brain amyloidosis with candidate GMB taxa, 
known to have inflammatory properties, and peripheral blood inflammation biomarkers. We found that 
subjects with cognitive impairment and brain amyloidosis had lower abundance of the anti-inflammatory 
Eubacterium rectale and higher abundance of the pro-inflammatory Escherichia/Shigella in their stools 
when they were compared to both a group of control subjects and also to a group of subjects with 
cognitive impairment and amyloid-negative.  
Consistently, Amy+ showed higher levels of the pro-inflammatory cytokines IL-6, CXCL2, NLRP3 and 
IL-1β, as well as reduced levels of the anti-inflammatory cytokine IL-10.  Interestingly, the abundance of 
Escherichia/Shigella correlated positively with the levels of IL-1β, CXCL2, NLRP3, whereas 
Eubacterium rectale correlated negatively with the levels of IL-1β, CXCL2 and NLRP3 and positively 
with IL-10. 
To our best knowledge, this is the first study reporting clinical evidence of GMB alterations in patients 
with brain amyloidosis. Previous experimental and neuropathological studies have suggested a possible 
involvement of GMB composition in AD pathogenesis. Recent data show that bacterial endotoxins may 
exert a key role in the inflammatory and pathological processes associated with amyloidosis and AD 
(Asti, Gioglio, 2014), as a co-incubation of Aβ with Escherichia endotoxins caused a potentiation of the 
in vitro Aβ fibrillogenesis. Bacterial components, such as endotoxins, have indeed been found within the 
typical senile plaque lesions of the AD brains (Asti, Gioglio, 2014; Schwartz et al., 2013). Recently, 
Kamer and collaborators (Kamer et al., 2016) have shown that clinical measures of periodontal disease in 
cognitively normal healthy elders are positively associated with the severity of brain amyloid 
accumulation assessed by [11C] PIB-PET, suggesting that dysbiosis related to chronic periodontal 
inflammation/infection may be involved in AD pathogenesis.   
In our study, the abundance of the genus Escherichia/Shigella was significantly increased in Amy+ 
compared to Amy- patients. Escherichia/Shigella has been associated with a pro-inflammatory status 
(Morgan et al., 2013; Soares et al., 2012b) and, in a recent study, Small and collaborators (Small et al., 
2013) found that persistent infection with adherent and invasive Escherichia led to chronic and persistent 
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peripheral inflammation. Also De La Fuente and collaborators reported an ability of the genus 
Escherichia to induce the production of pro-inflammatory cytokines through NLRP3-dependent 
mechanism (de la Fluente et al., 2014). Interestingly, in line with the studies mentioned above, we found a 
positive correlation between changes in the abundance of Escherichia/Shigella and changes in the levels 
of the pro-inflammatory molecules IL-6, CXCL2 and NLRP3, which is consistent with a possible cause-
effect relationship (Huang et al., 2015).  Of particular interest is the NLRP3 inflammasome, whose 
activation leads to the induction of inflammatory processes, including the maturation and the release of 
several pro-inflammatory cytokines and chemokines. Once activated, it can also promote the formation of 
inflammatory crystals and protein aggregates, including Aβ. NLRP3 production has been found enhanced 
in the brain of AD patients (Halle et al., 2008; Martinon et al., 2009) and an NLRP3 inflammasome 
deficiency resulted in decreased pro-inflammatory cytokines release and decreased deposition of Aβ in 
the APP/PS1 animal model of AD (Heneka et al., 2013). 
We also identified a significant reduction in Eubacterium rectale abundance in Amy+ as compared to 
Amy- subjects. Eubacterium rectale is a bacteria known to produce butyrate (an anti-inflammatory 
compound) that plays key protective roles against inflammation (Pryde et al., 2002). A reduction in its 
abundance correlated negatively with pro-inflammatory molecules in our sample, denoting enhanced 
sensitivity to inflammatory processes. This is in line with recent evidence indicating that an increase in 
Eubacterium rectale abundance is associated with lesser degree of inflammation. An increase in 
Eubacterium rectale also predicted positive response to treatment with anti-TNF-α, in patients with 
Inflammatory Bowel Disease (Kolho et al., 2015). 
Our findings may also be interpreted at the light of recent data regarding other neurological disorders, 
including multiple sclerosis (MS) and Parkinson’s disease (PD) that share with AD neuroinflammation 
and protein misfolding, respectively. In MS, studies in animal models and in germ-free mice (Forsythe et 
al., 2013; Lee et al., 2011) showed that GMB modifications may cause the activation of immune and 
inflammatory responses that can extend beyond the gut, up to the brain. In PD patients, changes in the 
GMB composition have been recently observed (Scheperjans et al., 2015; Keshavarzian et al., 2015; 
Hasegawa et al., 2015), and also, as alterations in the gut barrier function, membrane permeability, and 
inflammatory mediators production have been reported as affecting not only gut immune epithelial cells 
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and immune system cells, but also neurons and glial cells in PD patients (Forsyth et al., 2011). Moreover, 
specific bacteria taxa or their metabolites may trigger D-synuclein misfolding (Chorell et al., 2015; Evans 
et al., 2015). 
Two interesting studies (Keshavarzian et al., 2015; Hasegawa et al., 2015) provide evidence that pro-
inflammatory dysbiosis could trigger inflammation-induced misfolding of α-synuclein and promote the 
development of PD. In the Keshavarzian’s study, mucosal-associated and microbiota compositions were 
analyzed using high throughput ribosomal RNA gene sequencing, showing higher abundance of the anti-
inflammatory butyrate-producing bacteria in the feces of controls as compared to PD patients. Moreover, 
an increase of Faecalibacterium and a reduction of Proteobacteria were found in the mucosa of controls 
compared to PD patients. In the other study, Hasegawa and colleagues measured serum markers and 
quantified 19 fecal bacterial taxa by qPCR in a group of PD patients compared to healthy controls. The 
authors found that the abundance of Lactobacilli was higher whereas those of Clostridium coccoides and 
Bacteroides fragilis was lower in PD patients than in controls.  
In this scenario, we can hypothesize that the role of GMB composition in AD may be multiple. Indeed, 
specific GMB taxa may cause, as also supported by our data, the induction of immune and inflammatory 
responses in the brain, which in turn may induce Aβ deposition. However, we cannot exclude that 
alternative mechanisms exist, including the possible ability of GMB taxa or their metabolites to directly 
trigger protein misfolding and aggregation. Toxic forms of neurodegenerative diseases have been 
described, such as ALS-dementia complex of Guam (Cox et al., 2003) due to N-β-methylamino-L-alanine 
(BMAA) produced by Cyanobacteria (Cox et al., 2005).  
This study has some limitations. First, the cross-sectional nature of the study prevents to test a possible 
causal relationship, and any pathophysiological pathway leading from GMB composition, to 
neuroinflammation, to brain amyloidosis and lately to AD. Second, we have not used the most current 
standard methods for GMB assessment that is the next generation sequencing (NGS), but we have 
investigated 6 specific taxa. However, if the added value of NGS is to identify, by using a hypothesis free 
approach, all the possible taxa differentially modulated in a pathological condition, it is also true that for 
most of bacterial taxa the physiological properties are still poorly understood. This is the reason we used 
specific hypothesis driven approach and thus we selected taxa with inflammatory properties as we aimed 
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to assess the specific hypothesis that alterations in the abundance of specific gut taxa may be associated 
with alterations in the inflammatory status in the periphery and amyloidosis at the central level.  
Third, we lack information about the dietary habits of our patients. We are aware that long-term dietary 
differences can have major effects on the microbiome composition (Holmes et al., 2012; Cryan et al., 
2012), and this issue deserves further investigation. The 3 points difference in the MMSE of Amy+ and 
Amy- subjects may be interpreted as a downstream detrimental effect of brain amyloidosis on cognitive 
performance. However, this deserves further investigation, both as to its possible significance as to the 
role of GMB, and for careful control of this confounder in future studies. 
In conclusion, our data indicate that an increase in the abundance of a pro-inflammatory GMB taxon, 
Escherichia/Shigella, and a reduction in the abundance of an anti-inflammatory taxon, Eubacterium 
rectale, are possibly associated with a peripheral inflammatory state in patients with cognitive impairment 
and brain amyloidosis. This finding leads to the hypothesis that the GMB composition may drive 
peripheral inflammation, contributing to brain amyloidosis and, possibly, neurodegeneration and 
cognitive symptoms in AD. Further studies are needed to explore this possible causative role of GMB 
composition in inflammatory changes and brain amyloidosis. 
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Legends to Tables and Figures 
 
Table 1: Demographic and clinical features of study participants. 
Numbers denote mean ± standard deviation. p indicates the significance of the group differences on 
Students’ t or chi-square test.  
 
Figure 1. Abundance of bacterial taxa in the stools of study participants. 
Bars denote Fold changes (FC) of difference in amyloid positive (Amy+) and amyloid-negative (Amy-) 
patients versus control subjects (HC). The FC has been calculated using control subjects as reference 
(represented by the threshold line at zero), according to the ∆∆Ct method (for details see methods). * 
Statistical significance at p<0.05, ** at p<0.01 and *** at p<0.001 when comparing Amy+ and Amy- vs 
HC; # Statistical significance at p<0.001 when comparing Amy+ vs Amy-. 
 
Figure 2. Expression levels of inflammation-related cytokines in the blood of study participants 
Data are shown as Relative Expression Ratio of gene expression in control subjects (HC), amyloid 
positive (Amy+) and amyloid negative (Amy-) patients. Bars denote mean ± standard error. * Statistical 
significance at p<0.05 and ** at p<0.001 when comparing Amy+ or Amy- vs HC; # Statistical 
significance at p<0.05 when comparing Amy+ vs Amy-. 
 
Figure 3. Spearman correlation of cytokines blood levels with Escherichia/Shigella stool abundance 
in study participants. 
Cytokines (in the y axis) and Escherichia/Shigella (in the x axis) were selected based on the significance 
of the difference between groups. Full dots denote control subjects, open dots denote amyloid positive 
(Amy+) and open diamonds amyloid negative patients (Amy-). The graph shows Spearman correlations 
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rho-values and locally-weighted polynomial fitted curves (in black line) with relative 95% confidence 
band (in dotted line) obtained by a smoother span parameter equal to 100%.  
 
Figure 4. Spearman correlation of cytokines blood levels with Eubacterium rectale abundance in the 
stools in study participants. 
Cytokines (in the y axis) and Eubacterium rectale abundance (in the x axis) were selected based on 
significance of the difference between groups. Full dots denote control subjects, open dots denote amyloid 
positive (Amy+) and open diamonds amyloid negative patients (Amy-). The graph shows Spearman 
correlations rho-values and locally-weighted polynomial fitted curves (in black line) with relative 95% 
confidence band (in dotted line) obtained by a smoother span parameter equal to 100%.  
 
Supplementary Figure 1: PET scans with 18F-Florbetapir in exemplary study participants.  
Tracer uptake is represented with a color map superimposed on the individual CT scan of exemplary 
cases. Unspecific tracer uptake confined to the white matter is present in control subjects and Amy- 
patients (left and middle panels). Amy+ patients feature, in addition to unspecific uptake, specific tracer 
uptake in the cortex (right panel). 
 
Supplementary Table 1: Psychological assessment evaluation in study participants.  
Assessment included evaluation of:  
- global cognition (Mini-Mental State Examination MMSE, and Alzheimer’s Disease Assessment 
Scale – Cognitive ADAS-COG);  
- long-term memory (Story Recall Test, Rey Auditory-Verbal Learning Test – immediate and 
delayed recall (Rey AVLT), and Recall of Rey-Osterrieth Complex Figure);  
- attention (Trail Making Test – Part A TMT-A);  
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- language (Token Test, Action and Object naming -subtest from the Battery for Analysis of 
Aphasic Deficits, BADA-, and Letter and Category Fluency);  
- constructional and visuo-spatial abilities (Copy of Rey-Osterrieth Complex Figure);  
- upper limb apraxia (Movement imitation Test);  
- executive functions (Trail Making Test – Part B (TMT-B), and Wisconsin Card Sorting Test 
(WCST));  
- non-verbal reasoning (Raven’s Coloured Progressive Matrices (Raven’s CPM)).  
Numbers denote the mean values of test results ± standard deviation. 
 
Supplementary Table 2: List of current medications in study participants. 
Table show the current medications in Amy+ and Amy- patients with numbers denoting percentage (%) 
of subjects. 
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  Amy+ 
(n=40) 
Amy- 
(n=33) 
HC 
(n=10) 
Significance 
(p) 
Age (years) 71 ± 7 70 ± 7 68 ± 8 n.s. 
Females 20/40 18/34 6/10 n.s. 
Body Mass Index 24.5 ± 3.5 25.6 ± 3.7 24.3 ± 2.9 n.s. 
Mini Mental 
State Exam  
21.3 ± 6.1 25.5 ± 3.9 28.3 ± 1.1 p<0.01 Amy+ vs Amy-; 
p<0.05 Amy+ vs HC 
 
Table 1: Demographic and clinical features of study participants. 
 
Table 1
 Patients AMY 
negative (n=33) 
Patients AMY 
positive (n=40) 
HC AMY 
negative (n=10) 
GL
OB
AL
 
CO
GN
IT
IO
N 
MMSE 25.52 ± 3.87 21.30 ± 6.09 28.30 ± 1.06 
ADAS-COG 14.47 ± 9.75 19.93 ± 10.68 7.63 ± 2.25 
M
EM
OR
Y 
AS
SE
SS
M
EN
T Story Recall Test 8.14 ± 4.78 4.82 ± 4.34 10.40 ± 2.80 
Immediate Rey AVLT 32.03 ± 9.19 26.27 ± 11.10 39.80 ± 8.12 
Delayed Rey AVLT 5.24 ± 2.94 2.33 ± 2.78 7.90 ± 2.73 
Recall of Rey-Osterrieth 
Complex Figure 8.40 ± 5.03 4.82 ± 5.40 13.30 ± 3.26 
LA
NG
UA
GE
 TOKEN TEST 29.85 ± 4.40 27.65 ± 5.81 33.20 ± 1.42 
BADA (object naming) 25.87 ± 4.27 25.67 ± 2.99 28.20 ± 1.23 
BADA (action naming) 23.52 ± 3.49 21.57 ± 4.40 21.50 ± 1.72 
Category Fluency 29.74 ± 9.33 27.53 ± 10.49 36.80 ± 14.43 
Letter Fluency 25.61 ± 8.83 30.07 ± 12.98 39.60 ± 8.46 
Co
ns
tru
cti
on
al 
an
d v
isu
o-s
pa
tia
l 
ab
ilit
ies
 
Copy of Rey-Osterrieth 
Complex Figure 27.62 ± 6.38 25.30 ± 10.00 30.50 ± 2.71 
Up
pe
r L
im
b 
ap
ra
xia
 Movement imitation Test 
(DX) 64.80 ± 5.10 62.33 ± 7.53 67.50 ± 3.14 
Movement imitation Test 
(SX) 67.31 ± 4.48 63.31 ± 8.84 69.50 ± 2.88 
Ex
ec
ut
ive
 F
un
cti
on
 
WCST (GLOBAL 
SCORE) 79.33 ± 35.28 89.10 ± 33.02 105.00 ± 11.60 
TMT-A 65.06 ± 34.75 95.55 ± 90.99 43.70 ± 22.38 
TMT-B 189.88 ± 95.93 217.53 ± 121.32 133.60 ± 69.12 
TMT(B-A) 137.59 ± 81.04 151.06 ± 107.15 89.90 ± 63.18 
No
n-
ve
rb
al 
re
as
on
ing
 
Raven’s CPM 21.85 ± 6.12 17.92 ± 9.39 27.40 ± 5.42 
 
Supplementary Table 1 
Psychological assessment evaluations in study participants. 
Supplementary Table 1
  
 Amy-  
(n=33) 
Amy+  
(n=40) 
yes no n.a. yes no n.a. 
Anticholinesterases and anticholinergic drugs  3 (9.1%) 29 (87.9%) 1 (3%) 24 (60%) 13 (32.5%) 3 (7.5%) 
NMDA Receptor Antagonists 0 (0%) 32 (97%) 1 (3%) 8 (20%) 29 (72.5%) 3 (7.5%) 
Antihistamines  0 (0%) 32 (97%) 1 (3%) 2 (5%) 35 (87.5%) 3 (7.5%) 
Dyslipidemia drugs  3 (9.1%) 29 (87.9%) 1 (3%) 7 (17.5%) 30 (75%) 3 (7.5%) 
Hypertension medications  5 (15.2%) 27 (81.8%) 1 (3%) 11 (27.5%) 26 (65%) 3 (7.5%) 
Antipsychotics  2 (6.1%) 30 (90.9%) 1 (3%) 3 (7.5%) 34 (85%) 3 (7.5%) 
Benzodiazepines  5 (15.2%) 21 (63.6%) 7 (21.2%) 7 (17.5%) 27 (67.5%) 6 (15%) 
Antidepressants 9 (27.3%) 17 (51.5%) 7 (21.2%) 16 (40%) 18 (45%) 6 (15%) 
Hypoglycemic drugs  1 (3%) 31 (94%) 1 (3%) 1 (2.5%) 36 (90%) 3 (7.5%) 
Gastroprotective drugs 2 (6.1%) 30 (90.9%) 1 (3%) 5 (12.5%) 32 (80%) 3 (7.5%) 
Anticoagulants  1 (3%) 31 (94%) 1 (3%) 4 (10) 33 (82.5%) 3 (7.5%) 
 
Supplementary Table 2 
List of concomitant medications in Amy+ and Amy- patients. Numbers denote % of patients in each group (yes/no/not available) 
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